Spurious dyslipidemia due to paraprotein in a patient with Waldenström macroglobulinemia
- 5 August 2024
- journal article
- research article
- Published by Elsevier in Clinica Chimica Acta
- Vol. 563, 119900
Abstract
No abstract availableKeywords
Funding Information
- Sichuan Provincial Science and Technology Support Program (2021YFS0148)
This publication has 23 references indexed in Scilit:
- Clinical laboratory characteristics of patients with obstructive jaundice accompanied by dyslipidemiaClinical Biochemistry, 2021
- Lipoproteins and lipids in cardiovascular disease: from mechanistic insights to therapeutic targetingAdvanced Drug Delivery Reviews, 2020
- Artifactual measurement of low serum HDL-cholesterol due to paraproteinemiaClinical Research in Cardiology, 2010
- Differential reactivities of four homogeneous assays for LDL-cholesterol in serum to intermediate-density lipoproteins and small dense LDL: Comparisons with the Friedewald equationClinica Chimica Acta, 2009
- Case 40-2006New England Journal of Medicine, 2006
- New HDL-cholesterol reagent formulation reduces interference from samples with abnormal proteinsClinica Chimica Acta, 2006
- Historical milestones in measurement of HDL-cholesterol: Impact on clinical and laboratory practiceClinica Chimica Acta, 2006
- Falsely low LDL-cholesterol concentrations and artifactual undetectable HDL-cholesterol measured by direct methods in a patient with monoclonal paraproteinClinica Chimica Acta, 2005
- Apolipoprotein B and apolipoprotein A‐I: risk indicators of coronary heart disease and targets for lipid‐modifying therapyJournal of Internal Medicine, 2004
- High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective studyThe Lancet, 2001